WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。